tiprankstipranks
Trending News
More News >

Innovative Pharmaceutical Biotech Issues Profit Warning and Delays Product Launch

Story Highlights
Innovative Pharmaceutical Biotech Issues Profit Warning and Delays Product Launch

Don’t Miss TipRanks’ Half-Year Sale

Innovative Pharmaceutical Biotech ( (HK:0399) ) has issued an announcement.

Innovative Pharmaceutical Biotech Limited has issued a profit warning, anticipating a net loss between HK$550 million to HK$600 million for the fiscal year ending March 2025, primarily due to significant impairment losses on intangible assets and interest expenses on convertible bonds. The company also announced a delay in the commercialization of its oral insulin product, originally planned for early 2026, now postponed to the third quarter of 2028 due to challenges in clinical trial procedures and patient enrollment, impacting its operational timeline and market strategy.

More about Innovative Pharmaceutical Biotech

Innovative Pharmaceutical Biotech Limited operates in the pharmaceutical and biotechnology industry, focusing on the development and commercialization of innovative medical products, including an oral insulin product currently in clinical trials.

Average Trading Volume: 2,017,336

Technical Sentiment Signal: Buy

Current Market Cap: HK$379M

Find detailed analytics on 0399 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1